GetTopicDetailResponse(id=66971e4854b, topicName=Tislelizumab, introduction=Tislelizumab, content=null, image=null, comments=1, allHits=1518, url=https://h5.medsci.cn/topic?id=17485, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=97104, tagList=[TagDto(tagId=97104, tagName=Tislelizumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2207444, encodeId=777e220e444e1, content=<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化療#</a> <a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=66971e4854b' target=_blank style='color:#2F92EE;'>#Tislelizumab#</a>, objectTitle=總生存期近17個(gè)月！BMJ：這類(lèi)胃癌患者治療獲益更大，死亡風(fēng)險(xiǎn)更低, objectType=article, longId=828160, objectId=f23982816049, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240530/1717044321201_5579292.jpg, objectUrl=/article/show_article.do?id=f23982816049, replyNumber=0, likeNumber=133, createdTime=2024-05-30, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f23982816049, moduleTitle=總生存期近17個(gè)月！BMJ：這類(lèi)胃癌患者治療獲益更大，死亡風(fēng)險(xiǎn)更低, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f23982816049)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=801016, encodeId=c5d58010166f, content=<a href='/topic/show?id=66971e4854b' target=_blank style='color:#2F92EE;'>#Tislelizumab#</a>肝癌, objectTitle=百濟(jì)神州PD-1單抗Tislelizumab治療肝細(xì)胞癌的新藥申請(qǐng)被NMPA接受，以及Tislelizumab抗腫瘤臨床研究匯總, objectType=article, longId=196984, objectId=1327196984da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200624/936fa7d1d50f4bc1b75c5e203ba12504.jpg, objectUrl=/article/show_article.do?id=1327196984da, replyNumber=0, likeNumber=209, createdTime=2020-07-03, rootId=0, userName=mswert122, userId=2a791737770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1327196984da, moduleTitle=百濟(jì)神州PD-1單抗Tislelizumab治療肝細(xì)胞癌的新藥申請(qǐng)被NMPA接受，以及Tislelizumab抗腫瘤臨床研究匯總, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1327196984da)], followStatus=false, userIsMember=true, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
